CENTENIAL SURGICAL SUTURE LTD. is a Healthcare Equipment & Supplies company. The annual-report business brief for this company has not been generated yet; the numbers below are as filed.
| ₹ crore · consolidated | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Revenue | 44 | 53 | 51 | 54 | 54 |
| EBITDA (ex other income) | 4 | 4 | 5 | 6 | 5 |
| margin % | 10.0 | 8.2 | 9.8 | 11.7 | 9.5 |
| Owners' profit | 1 | 1 | 1 | (1) | (2) |
| EPS, as reported (₹) | 1.72 | 2.43 | 3.11 | 4.01 | 6.04 |
| ROE % · ROCE % | 2.1 · 8.0 | 3.2 · 8.4 | 3.5 · 8.1 | (4.8) · 4.0 | (7.7) · 2.6 |
| Debt / equity (x) | 0.00 | 0.00 | 0.00 | 0.40 | 0.38 |
| Cash from operations | 3 | (0) | 4 | 14 | 4 |
| Capex | (0) | (0) | (8) | (11) | (2) |
| ₹ crore | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 14 | 12 | 13 | 13 | 13 | 15 | 13 | 15 |
| Profit before tax | 0 | (1) | (1) | (0) | (0) | 0 | (2) | 1 |
| Net profit | 0 | (1) | (1) | (0) | (0) | 0 | (2) | 1 |
| EPS (₹) | 0.35 | (2.30) | 3.24 | 0.11 | 0.03 | 0.40 | 6.34 | 2.01 |
| Company | M.cap ₹ cr | P/E | P/B | EV/EBITDA | ROE % | ROCE % | Rev CAGR 5y % | EBITDA m. % |
|---|---|---|---|---|---|---|---|---|
| POLY MEDICURE LIMITED | 17,626 | 55.9 | 5.60 | 32.3 | 10.2 | 12.6 | 19.0 | 30.2 |
| FISCHER MEDICAL VENTURE L | 2,353 | 15.0 | 6.11 | 43.6 | 8.1 | 11.3 | — | 15.5 |
| TARSONS PRODUCTS LIMITED | 1,657 | 149.0 | 2.61 | 14.3 | 2.3 | 2.4 | — | 29.0 |
| LAXMI DENTAL LIMITED | 1,121 | 36.0 | 4.59 | 24.1 | 11.8 | 11.0 | — | 22.3 |
| Date · filing | Category | Importance | 1-day % | 5-day % |
|---|---|---|---|---|
| 11 Sept 2026 · CFO change at Centenial Surgical Suture | compliance | high | — | — |
| 3 Sept 2026 · 31st e-AGM Notice Published in Newspapers with E-Voting Details | compliance | minimal | — | — |
| 1 Sept 2026 · 31st Annual Report FY2025-26 submitted; AGM on September 28, 2026 | compliance | medium | — | — |
| 1 Sept 2026 · 31st AGM notice - e-AGM on September 28, 2026 | board shareholder meetings | low | — | — |
| 1 Sept 2026 · Centenial Surgical Suture sends 31st AGM notice and FY26 Annual Report | compliance | minimal | — | — |
| 26 Aug 2026 · Company flags suspected price manipulation, seeks SEBI and BSE probe | regulatory legal | high | — | — |
| 17 Aug 2026 · Newspaper publication of Q1 FY27 unaudited results | compliance | minimal | — | — |
| 3 Aug 2026 · Board meeting on Aug 14 to consider Q1 FY26-27 results, AGM | results | low | — | — |
| 8 Jul 2026 · Compliance certificate for Q1 FY27 under SEBI Regulation 74(5) | compliance | minimal | — | — |
| 24 Jun 2026 · President-Production Mr. Sanjay Sohani retires from the company | management changes | medium | — | — |
| Where a broker report shows | This document shows | Why |
|---|---|---|
| A rating (BUY / ADD / REDUCE / SELL) | A state: the latest filed quarter and the measured reactions | an event is a fact; a rating is an opinion that requires SEBI RA registration |
| FABTECH TECHNOLOGIES LTD | 650 | 10.6 | 1.55 | 10.6 | 9.1 | 10.7 | — | 9.9 |
| Hemant Surgical Industries Lim | 613 | 23.4 | — | — | — | 16.7 | — | — |
| Prevest Denpro Limited | 489 | 16.5 | — | — | — | 21.9 | — | — |
| NURECA LIMITED | 318 | 65.2 | 1.76 | 38.3 | 1.2 | 2.7 | (7.2) | 13.0 |
| Metric | Company | Group median | Rank | Better than |
|---|---|---|---|---|
| P/E (TTM) | 11.1 | 20.0 | 4 of 17 | 81% |
| P/B | 1.2 | 2.7 | 2 of 11 | 90% |
| ROCE | (4.3) | 11.3 | 17 of 17 | 0% |
| ROE | (7.7) | 8.1 | 11 of 11 | 0% |
| Debt / Equity | 0.4 | 0.1 | 10 of 11 | 10% |
| EBITDA margin | 14.3 | 16.7 | 8 of 11 | 30% |
| Revenue growth | 18.6 | 13.9 | 5 of 13 | 67% |
| Profit growth | 1980.0 | 75.5 | 1 of 10 | 100% |
| Market cap | 35 | 175 | 15 of 17 | 13% |
| A target price and upside | The current price and the multiples against the group | a target is a forecast; a multiple is a measurement |
| Estimate years marked E | More audited years; no estimates | MarketPing publishes no forecasts — your own model lives on the Models page |
This document is a statistical summary of publicly filed information and market data, prepared by software from primary sources: SEBI results XBRL filed with BSE and NSE, LODR disclosures, shareholding patterns, exchange price data. It contains no research recommendation, no price target and no opinion on the merits of any security, and is not a research report within the meaning of the SEBI (Research Analysts) Regulations, 2014, Regulation 2(1)(w)(vii). Financial statements are as filed (consolidated where the company files consolidated results). Ratios are computed over filed lines. Where a figure is unavailable the table shows a dash rather than an estimate. The business brief is written by MarketPing's reader from the annual report and checked against it; no figure in a table was generated by a model. Nothing here constitutes investment advice, an offer or a solicitation; readers should consult a SEBI-registered adviser before acting. MarketPing is not a SEBI-registered intermediary.
